(-0.22%) 5 011.12 points
(0.06%) 37 775 points
(-0.52%) 15 601 points
(-0.24%) $82.49
(1.52%) $1.738
(0.19%) $2 392.90
(-0.37%) $28.30
(-0.53%) $949.10
(0.28%) $0.939
(0.56%) $11.05
(0.17%) $0.804
(-0.17%) $93.90
5 days till quarter result
(bmo 2024-04-23)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally...
Stats | |
---|---|
Today's Volume | 293 017 |
Average Volume | 60 086.00 |
Market Cap | 1.58B |
EPS | SEK0 ( 2024-02-22 ) |
Next earnings date | ( SEK0 ) 2024-04-23 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -4.77 |
ATR14 | SEK0.0950 (0.40%) |
Volume Correlation
BioInvent International Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
BioInvent International Correlation - Currency/Commodity
BioInvent International Financials
Annual | 2023 |
Revenue: | SEK71.46M |
Gross Profit: | SEK71.46M (100.00 %) |
EPS: | SEK-5.02 |
Q4 | 2023 |
Revenue: | SEK15.32M |
Gross Profit: | SEK15.32M (100.00 %) |
EPS: | SEK-1.480 |
Q3 | 2023 |
Revenue: | SEK26.80M |
Gross Profit: | SEK26.80M (100.00 %) |
EPS: | SEK-1.080 |
Q2 | 2023 |
Revenue: | SEK13.10M |
Gross Profit: | SEK13.10M (100.00 %) |
EPS: | SEK-1.340 |
Financial Reports:
No articles found.
BioInvent International
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators